Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study
Open Access
- 26 April 2022
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 16 (5) , 906-915
Abstract
Background: Influenza and respiratory syncytial virus (RSV) are associated with substantial morbidity and mortality in the United States. We assessed risk factors for severe disease and medical resource utilization (MRU) among US adults hospitalized with influenza or RSV in the Hospitalized Acute Respiratory Tract Infection (HARTI) study.Methods: HARTI was a prospective global (40 centers, 12 countries) epidemiological study of adults hospitalized with acute respiratory tract infections conducted across the 2017–2019 epidemic seasons. Patients with confirmed influenza or RSV were followed up to 3 months post‐discharge. Baseline characteristics, prevalence of core risk factors (CRFs) for severe disease (age ≥65 years, chronic heart or renal disease, chronic obstructive pulmonary disease, or asthma), and MRU were summarized descriptively.Results: The US cohort included 280 influenza‐positive and 120 RSV‐positive patients. RSV patients were older (mean: 63.1 vs. 59.7 years) and a higher proportion had CRFs (87.5% vs. 81.4%). Among those with CRFs (influenza, n = 153; RSV, n = 99), RSV patients required longer hospitalizations (median length of stay: 4.5 days) and a greater proportion (79.8%) required oxygen supplementation during hospitalization compared with influenza patients (4.0 days and 59.5%, respectively). At 3 months post‐discharge, a greater proportion of RSV patients with CRFs reported use of antibiotics, antitussives, bronchodilators, and inhaled and systemic steroids versus those with influenza and CRFs. Many patients with CRFs reported hospital readmission at 3 months post‐discharge (RSV: 13.4%; influenza: 11.9%).Conclusions: MRU during and post‐hospitalization due to RSV in adults is similar to or greater than that of influenza. Enhanced RSV surveillance and preventive and therapeutic interventions are needed.Keywords
Funding Information
- Janssen Pharmaceutica
This publication has 36 references indexed in Scilit:
- Estimating the hospitalization burden associated with influenza and respiratory syncytial virus in New York City, 2003–2011Influenza and Other Respiratory Viruses, 2015
- Respiratory Syncytial Virus Surveillance in the United States, 2007–2012The Pediatric Infectious Disease Journal, 2014
- The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and deathResuscitation, 2013
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Rates of Hospitalizations for Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza Virus in Older AdultsThe Journal of Infectious Diseases, 2012
- Evidence for a causal relationship between respiratory syncytial virus infection and asthmaExpert Review of Anti-infective Therapy, 2011
- Systematic Review of Emergency Department Crowding: Causes, Effects, and SolutionsAnnals of Emergency Medicine, 2008
- The annual impact of seasonal influenza in the US: Measuring disease burden and costsVaccine, 2007
- Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2003
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003